Fig. 1From: Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)Mean (SE) MMD and PRN rimegepant 75 mg tablet use over time for patients in BHV3000–201. MMD = monthly migraine days; PRN = as neededBack to article page